Email this article The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
- Authors: Borisov K.E.1
-
Affiliations:
- Bashkirsky State Medical University
- Issue: No 1 (2012)
- Pages: 102-112
- Section: GYNECOLOGY. TREATMENT
- Published: 23.02.2012
- URL: https://ojrs.abvpress.ru/ojrs/article/view/88
- DOI: https://doi.org/10.17650/1994-4098-2012-0-1-102-112
- ID: 88
Cite item
Full Text
Abstract
The review presents data on the efficacy of topoisomerase I inhibitor topotecan in patients with recurrent ovarian cancer when compared with other chemotherapeutic agents. It is shown that topotecan may be the drug of choice for platinum-resistant relapse. To reduce the hemato- logic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime.
About the authors
K. E. Borisov
Bashkirsky State Medical University
Author for correspondence.
Email: konstantin9671@rambler.ru
Russian Federation
References
Supplementary files
